Our top pick for
Zomedica Corp is a drug manufacturers-specialty & generic business based in the US. Zomedica shares (ZOM) are listed on the NYSE MKT and all prices are listed in US Dollars. Zomedica employs 19 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.50|
|52-week range||$0.06 - $2.90|
|50-day moving average||$0.53|
|200-day moving average||$0.72|
|Wall St. target price||$1.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.07|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-3.11%|
|1 month (2021-09-23)||-5.85%|
|3 months (2021-07-23)||-20.54%|
|6 months (2021-04-23)||-47.08%|
|1 year (2020-10-23)||556.58%|
|2 years (2019-10-24)||62.43%|
|3 years (2018-10-24)||1.55|
|5 years (2016-10-24)||1.3154|
|Gross profit TTM||$0|
|Return on assets TTM||-7.32%|
|Return on equity TTM||-11.71%|
|Market capitalisation||$488.9 million|
TTM: trailing 12 months
There are currently 87.4 million Zomedica shares held short by investors – that's known as Zomedica's "short interest". This figure is 13.1% down from 100.6 million last month.
There are a few different ways that this level of interest in shorting Zomedica shares can be evaluated.
Zomedica's "short interest ratio" (SIR) is the quantity of Zomedica shares currently shorted divided by the average quantity of Zomedica shares traded daily (recently around 23.7 million). Zomedica's SIR currently stands at 3.69. In other words for every 100,000 Zomedica shares traded daily on the market, roughly 3690 shares are currently held short.
However Zomedica's short interest can also be evaluated against the total number of Zomedica shares, or, against the total number of tradable Zomedica shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zomedica's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Zomedica shares in existence, roughly 90 shares are currently held short) or 0.0905% of the tradable shares (for every 100,000 tradable Zomedica shares, roughly 91 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zomedica.
Find out more about how you can short Zomedica stock.
We're not expecting Zomedica to pay a dividend over the next 12 months.
Over the last 12 months, Zomedica's shares have ranged in value from as little as $0.063 up to $2.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Zomedica's is 0.419. This would suggest that Zomedica's shares are less volatile than average (for this exchange).
Zomedica Corp. , a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.